Literature DB >> 18957185

Update on adult attention-deficit/hyperactivity disorder.

Paul Hammerness1, Craig Surman, Katherine Miller.   

Abstract

Attention-deficit/hyperactivity disorder (ADHD) is a highly prevalent and highly morbid neurobehavioral disorder afflicting children, adolescents, and adults throughout the world. This article discusses the clinical assessment of adult ADHD, reviews the results of recent adult ADHD treatment studies with an emphasis on medications currently approved by the US Food and Drug Administration, and discusses the clinical management and monitoring of ADHD pharmacotherapy.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18957185     DOI： 10.1007/s11910-008-0077-z

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN： 1528-4042            Impact factor:   5.081


  31 in total

1.  Treatment of ADHD with stimulant medications: response to Nissen perspective in the New England Journal of Medicine.

Authors:  Joseph Biederman; Thomas J Spencer; Timothy E Wilens; Jefferson B Prince; Stephen V Faraone
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-10       Impact factor: 8.829

2.  ADHD drugs and cardiovascular risk.

Authors:  Steven E Nissen
Journal:  N Engl J Med       Date:  2006-03-20       Impact factor: 91.245

3.  Validity of the World Health Organization Adult ADHD Self-Report Scale (ASRS) Screener in a representative sample of health plan members.

Authors:  Ronald C Kessler; Lenard A Adler; Michael J Gruber; Chaitanya A Sarawate; Thomas Spencer; David L Van Brunt
Journal:  Int J Methods Psychiatr Res       Date:  2007       Impact factor: 4.035

4.  An open-label trial of OROS methylphenidate in adults with late-onset ADHD.

Authors:  Joseph Biederman; Eric Mick; Thomas Spencer; Craig Surman; Paul Hammerness; Robert Doyle; Megan Dougherty; Megan Aleardi; Karl Schweitzer
Journal:  CNS Spectr       Date:  2006-05       Impact factor: 3.790

5.  Psychometric properties of the Chinese version of the adult ADHD Self-report Scale.

Authors:  Chin-Bin Yeh; Susan Shur-Fen Gau; Ronald C Kessler; Yu-Yu Wu
Journal:  Int J Methods Psychiatr Res       Date:  2008       Impact factor: 4.035

6.  The prevalence and workplace costs of adult attention deficit hyperactivity disorder in a large manufacturing firm.

Authors:  R C Kessler; M Lane; P E Stang; D L Van Brunt
Journal:  Psychol Med       Date:  2008-04-21       Impact factor: 7.723

7.  Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder [corrected]: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing.

Authors:  Victoria L Vetter; Josephine Elia; Christopher Erickson; Stuart Berger; Nathan Blum; Karen Uzark; Catherine L Webb
Journal:  Circulation       Date:  2008-04-21       Impact factor: 29.690

8.  Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study.

Authors:  Lenard A Adler; Thomas J Spencer; David W Williams; Rodney J Moore; David Michelson
Journal:  J Atten Disord       Date:  2008-04-30       Impact factor: 3.256

9.  Atomoxetine treatment of adults with ADHD and comorbid alcohol use disorders.

Authors:  Timothy E Wilens; Lenard A Adler; Margaret D Weiss; David Michelson; Janet L Ramsey; Rodney J Moore; Didier Renard; Kathleen T Brady; Paula T Trzepacz; Leslie M Schuh; Lisa M Ahrbecker; Louise R Levine
Journal:  Drug Alcohol Depend       Date:  2008-04-09       Impact factor: 4.492

10.  Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies.

Authors:  David Michelson; Lenard Adler; Thomas Spencer; Frederick W Reimherr; Scott A West; Albert J Allen; Douglas Kelsey; Joachim Wernicke; Anthony Dietrich; Denái Milton
Journal:  Biol Psychiatry       Date:  2003-01-15       Impact factor: 13.382
View more
  3 in total

1.  Cost of illness and comorbidities in adults diagnosed with attention-deficit/hyperactivity disorder: a retrospective analysis.

Authors:  Paul Hodgkins; Leslie Montejano; Rahul Sasané; Dan Huse
Journal:  Prim Care Companion CNS Disord       Date:  2011

2.  Risk of injury associated with attention-deficit/hyperactivity disorder in adults enrolled in employer-sponsored health plans: a retrospective analysis.

Authors:  Paul Hodgkins; Leslie Montejano; Rahul Sasané; Dan Huse
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Methylphenidate hydrochloride modified-release in adults with attention deficit hyperactivity disorder: a randomized double-blind placebo-controlled trial.

Authors:  Michael Huss; Ylva Ginsberg; Torbjorn Tvedten; Torben Arngrim; Alexandra Philipsen; Katherine Carter; Chien-Wei Chen; Vinod Kumar
Journal:  Adv Ther       Date:  2013-12-27       Impact factor: 3.845
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.